Startup Deep Dive : CureSkin — still loses more than half of every rupee it earns

CureSkin started with one father who could not get a straight answer for his son’s skin problem from the dermatologists he could reach in Bengaluru. Two decades later that frustration is a Bengaluru company that books more than ₹108.0 crore ($11.25 million at $1 ≈ ₹96.0, 18 September 2026, Trading Economics) in FY25 revenue (Inc42, September 2026) — and still lost ₹67.9 crore doing it, more than 60 paise of every rupee it took in.

That is the contradiction sitting inside CureSkin’s growth story: a business that has scaled a scarce, expensive service — a dermatologist’s attention — to more than 1.5 million Indians, most of them outside the big metros, while its losses have widened faster than most of its revenue milestones. What follows traces how an app built to read photos of acne and pigmentation became a ₹100-crore-plus direct-to-consumer health business, why it took more than three years to raise real institutional money, and where the losses actually come from.

Quick facts

What CureSkin does

CureSkin sells a photo-led skin and hair diagnosis, delivered through an app, that ends in a dermatologist-approved treatment kit shipped to a customer’s door. A user photographs their face or scalp; CureSkin’s image-recognition system flags likely conditions — acne, pigmentation, dark spots, hair thinning and related issues — and a dermatologist on CureSkin’s own panel reviews the case and prescribes an eight-week regimen of cleansers, creams and, where needed, oral or topical medication, with follow-up check-ins built into the app (FactorDaily, archived; Entrackr, March 2024). The customer is typically not in Mumbai or Delhi: roughly 80% of CureSkin’s users come from Tier 2 and Tier 3 towns, where a visit to a qualified dermatologist can mean travelling to the nearest city (Entrackr, March 2024; YourStory, March 2024).

The origin

Guna Kakulapati had already built and sold one company — the ad-tech startup Bidstalk, acquired by AppLift in 2015 — when his son developed a skin condition that repeated visits to doctors around Bengaluru failed to properly diagnose (ascendants.in; FactorDaily, archived). India’s dermatologist shortage is not a minor gap: independent reporting has put the ratio at anywhere from roughly 6,600 to 11,000 qualified dermatologists for a population of more than 1.3 billion people, depending on the count used (ascendants.in; YourStory reporting, via search, 2019). Kakulapati, an IIT Madras graduate with a master’s in computer science from the University of Illinois Urbana-Champaign and machine-learning experience from stints at Google and Amazon, teamed up with fellow ex-Googler Ramakrishna Rajanna, who had spent roughly a decade on Google’s spam-detection systems, and dermatologist Dr Charu Sharma to see whether an image-recognition model could do the first pass of diagnosis that a dermatologist would otherwise have to do in person (FactorDaily, archived; YourStory reporting, via search, 2019). The company was built around that single bet: that a photo, read by a trained model and checked by a real dermatologist, could stand in for the first, hardest-to-get appointment.

The struggle years

CureSkin’s early years ran on very little capital by Indian startup standards. After being picked for Y Combinator’s Summer 2017 batch — the only Indian company in that year’s AI cohort, according to YourStory’s reporting — the company scaled on roughly $1 million or less pulled together from Y Combinator itself, Khosla Ventures, Gagarin Capital and Heartbeat Labs, per data compiled by Tracxn. There was no institutional seed round with a lead investor’s name attached to it until SenseAI Ventures wrote a $500,000 cheque on 28 January 2020, more than two and a half years after the YC batch (Tracxn investor data; YourStory reporting, via search, January 2020). By FY22, five full years after founding, CureSkin’s revenue was still just ₹2.57 crore (Entrackr, March 2024) — a scale that reflected years of slow, capital-starved growth rather than the rocket-ship trajectory the AI and Y Combinator tags might suggest.

The second constraint was structural rather than financial. For years the CureSkin business was held together as an LLP rather than a private limited company — a structure that does not lend itself to issuing the equity shares that venture investors need to take a stake. Public corporate records show the current operating entity, Cure and Care Wellness Private Limited, was only incorporated on 13 October 2021 (Registrar of Companies filing, via Tofler and Vakilsearch, CIN U85300KA2021PTC153059) — just five months before CureSkin’s first proper priced round. The company had to be legally rebuilt before it could take the institutional money its growth needed.

The turning point

The pivot came on 7 March 2022, when JSW Ventures led a $5 million Series A, with Sharrp Ventures, SenseAI and existing backers participating (Entrackr, March 2022; Inc42, March 2022). Before that round, CureSkin had raised roughly $1.5 million across five years of seed and angel money, and FY22 revenue sat at ₹2.57 crore. After it, revenue jumped to ₹35.46 crore in FY23 — more than 13 times FY22’s number — and the company would go on to raise a further $20 million Series B, led by HealthQuad, just two years later in March 2024 (Entrackr, March 2024). A single equity round, arriving five months after the company’s legal restructuring, is the point at which CureSkin stopped being a bootstrapped AI experiment and became a funded, fast-scaling consumer health business.

The money behind it

• Y Combinator, Summer 2017 batch: no priced round, but a validation stamp as the only Indian company in that year’s AI cohort, plus its standard seed cheque and network (YourStory reporting, via search, 2019).
• SenseAI Ventures, $500,000 seed, 28 January 2020: the first institutional investor with its name on a CureSkin round, backing the company’s stated goal of bringing dermatology to Tier 2 and Tier 3 towns (Tracxn; YourStory reporting, via search, January 2020).
• JSW Ventures, $5 million Series A lead, 7 March 2022: the round that followed the company’s conversion into a private limited entity and financed the scale-up that took revenue from ₹2.57 crore (FY22) to ₹35.46 crore (FY23) (Entrackr, March 2022).
• HealthQuad, $20 million Series B lead, 13 March 2024: India’s dedicated digital-health venture fund, joined by JSW Ventures, Khosla Ventures and Sharrp Ventures, took cumulative funding to about $26 million and was earmarked to expand CureSkin’s AI capability and product range (Entrackr, March 2024; BioSpectrum India, March 2024).
• Total raised — contested: Entrackr and YourStory put cumulative funding at $26 million as of the March 2024 Series B; Tracxn’s tracker shows additional Series B tranches in January 2025 and December 2025 and puts cumulative funding at $28.9–$30.1 million across up to seven rounds and 52 investors as of 2026. Both figures are given because the trackers do not agree on how many follow-on tranches count.

How it makes money

• Money in: CureSkin sells eight-week treatment kits — cleanser, moisturiser, repair cream and sun protection, plus prescription-strength actives where a dermatologist advises them — priced from roughly ₹1,499–1,800 per kit, sold directly to the customer through the app rather than through pharmacies or retail (FactorDaily, archived; cureskin.com pricing pages, via search).
• What’s bundled in: the price includes a dermatologist’s initial review, free follow-up check-ins through the app, and doorstep delivery, so a single purchase functions as consultation, prescription and product in one (FactorDaily, archived).
• Costs out: a panel of more than 50 dermatologists on staff or contract (ascendants.in), product manufacturing and logistics for physical kits shipped nationwide, and customer acquisition — FY25 total expenses grew 64% year-on-year to ₹175.9 crore against 32.0% revenue growth, meaning costs are currently scaling roughly twice as fast as sales (Inc42, September 2026).
• The part people get wrong: because CureSkin is described as an “AI dermatology app,” it reads like a software business. Its revenue line says otherwise — at over ₹100 crore a year on a base of physical treatment-kit sales, this is a direct-to-consumer health-and-beauty commerce company that uses an app as its diagnostic funnel and customer-relationship layer, not a subscription-software company monetising a photo tool.

The numbers

CureSkin’s revenue has compounded quickly since its Series A, but so have its losses. No published breakdown of gross margin, unit economics or take rate was found in RoC-sourced reporting, so none is asserted here.

Source: Inc42’s financials coverage of Cure and Care Wellness Private Limited (September 2026) and Entrackr’s March 2024 reporting on the company’s FY23 filing. FY24’s loss narrowed even as revenue nearly doubled from FY23, but FY25 broke that pattern — the loss nearly tripled even though revenue grew only 32.0%, the widest gap between revenue growth and loss growth in the three years for which figures were found.

Where the money comes from

• Geography — the real customer base: about 80% of CureSkin’s users are from Tier 2 and Tier 3 towns rather than metro India, a figure repeated consistently across Entrackr (March 2024), YourStory (March 2024) and ascendants.in reporting.
• Scale reached: more than 1.5 million people have been through CureSkin’s diagnosis-and-treatment funnel since launch, per company-stated figures cited in Entrackr and YourStory’s March 2024 coverage of the Series B.
• Product mix: skin conditions (acne, pigmentation, dark spots, dark circles) and hair conditions (hair thinning and loss) are both treated through the same app and kit model; no separate skin-versus-hair revenue split has been published (FactorDaily, archived; YourStory reporting, via search, 2019).
• The surprise: a company marketed as an AI health-tech story earns almost all of its money the way a mail-order pharmacy or D2C beauty brand would — from repeat sales of a physical kit to a mostly small-town customer base that a metro-focused beauty industry has largely ignored.

The risks

• Losses are widening faster than revenue: FY25 expenses grew 64% year-on-year against 32.0% revenue growth, and the net loss nearly tripled to ₹67.9 crore even as revenue crossed ₹100 crore for the first time (Inc42, September 2026) — a burn trajectory that, if it continues, would require either a sharp change in unit economics or further large funding rounds.
• A crowded, well-funded field: Tracxn’s own competitor tracking lists at least ten active rivals in AI-led skin and hair diagnosis and teleconsultation, including Clinikally, SkinKraft, Remedico and Traya, alongside beauty-commerce giants Nykaa and Purplle that can bundle dermatology-adjacent products into much larger platforms — meaning CureSkin’s Tier 2/3 advantage is not guaranteed to be uncontested for long.
• Headcount has been shrinking, not growing, into this loss-widening period: Tracxn’s tracked employee count shows roughly 101 staff as of August 2025, down from a year earlier — a contraction that sits awkwardly next to a tripling loss, and raises the question of where the FY25 expense growth actually went if not into headcount.

The takeaway

CureSkin’s arc is a reminder that a good diagnosis of a problem is not the same as a good business model for solving it. Reading a photo of someone’s skin with reasonable accuracy is a real technical achievement, and it opened a door to more than a million and a half Indians who could not otherwise reach a dermatologist. But turning that into a company meant becoming something much less glamorous than “AI health-tech” — a logistics-and-manufacturing operation shipping physical treatment kits at a loss, hoping that scale and better retention eventually bend the cost curve down faster than the revenue curve is bending up. The lesson transfers well beyond skincare: solving access is the interesting part of the pitch, but paying for the fulfilment behind it is the part that decides whether the business survives.

Frequently asked questions

What exactly does CureSkin sell?

An app-based photo diagnosis of skin and hair conditions, followed by a dermatologist-approved treatment kit — cleansers, creams and, where prescribed, medicated products — delivered to the customer’s home over an eight-week regimen with follow-up check-ins (FactorDaily, archived; Entrackr, March 2024).

Who founded CureSkin, and when?

Gunavardhan Kakulapati, Ramakrishna Rajanna and Dr Charu Sharma. FactorDaily’s reporting puts the founding in October 2016; most funding trackers, including Tracxn and Inc42, list 2017, the year of its Y Combinator Summer batch.

How much money has CureSkin raised, and from whom?

At least $26 million by its March 2024 Series B, led by HealthQuad with JSW Ventures, Khosla Ventures and Sharrp Ventures participating, on top of an earlier $5 million Series A led by JSW Ventures and a $500,000 SenseAI Ventures seed round (Entrackr, March 2022 and March 2024). Tracxn’s tracker shows the cumulative figure rising further, to $28.9–$30.1 million, after additional tranches in 2025.

Is CureSkin profitable?

No. It reported a net loss of ₹67.9 crore in FY25 on revenue of ₹108.0 crore, after a ₹25.2 crore loss in FY24 and a ₹28 crore loss in FY23 (Inc42, September 2026; Entrackr, March 2024). Its FY25 loss nearly tripled year-on-year even as revenue grew 32.0%.

What is CureSkin worth?

Inc42 puts its valuation at about $43.6 million as of the March 2024 Series B. Tracxn separately tracks a $46.8 million peak around March 2022, with the current mark estimated about 5% below that as of 2026. The two do not fully agree, so both figures are given here rather than a single number.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42, “CureSkin – Company Profile” and “CureSkin Financials 2026,” accessed September 2026
• Inc42, “AI-Driven Startup CureSkin Secures $5 Mn In Series A From JSW Ventures,” March 2022
• Entrackr, “CureSkin raises $5 Mn in Series A round,” March 2022
• Entrackr, “Y Combinator-backed CureSkin raises $20 Mn led by Healthquad,” March 2024
• YourStory, reporting on CureSkin’s Series B funding round, March 2024 (via search)
• YourStory, reporting on CureSkin’s founding and founders, June 2019 (via search)
• YourStory, reporting on CureSkin’s SenseAI Ventures seed round, January 2020 (via search)
• BioSpectrum India, “Bengaluru-based AI startup Cureskin secures $20 M in Series B funding round,” March 2024
• FactorDaily (archived), “This AI-enabled dermatology app aims to save Indians the blushes”
• ascendants.in, “CureSkin: From a Father’s Concern to AI-Driven Skincare Solutions”
• Tracxn, Cureskin company, funding and investor profile pages, accessed 2026
• Tofler, company filing summary for Cure and Care Wellness Private Limited (CIN U85300KA2021PTC153059), accessed September 2026
• Vakilsearch / IndiaFilings, corporate registration records for Cure and Care Wellness Private Limited, accessed September 2026
• Trading Economics, USD/INR exchange rate, 18 September 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.